NCT04797728View on ClinicalTrials.gov

Elacestrant in Preoperative Setting, a Window of Opportunity Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

February 8, 2022

Study Completion Date

February 25, 2022

Conditions
Breast CancerHormone Receptor Positive Breast Carcinoma
Interventions
DRUG

Elacestrant

Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)

Trial Locations (4)

08916

ICO Badalona, Badalona

08195

Hospital General de Catalunya, Sant Cugat del Vallès

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic Barcelona, Barcelona

All Listed Sponsors
collaborator

Radius Health, Inc.

INDUSTRY

lead

SOLTI Breast Cancer Research Group

OTHER

NCT04797728 - Elacestrant in Preoperative Setting, a Window of Opportunity Study | Biotech Hunter | Biotech Hunter